Bioventus Inc.

Bioventus Inc.

BVSยทNASDAQ

$8.55

+5.4%
HealthcareMedical - Devices

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

At a Glance

Live Snapshot
Market Cap$579.25M
EPS0.3400
P/E Ratio25.15
Earnings Date08/05/2026
3Y-50.0%
5Y+38.0%
10Y+59.0%
3Y-53.0%
5Y+30.0%
10Y+80.0%
3Y-45.0%
5Y+58.0%
10Y+29.0%
bvs

Bioventus Inc. Funding & Solvency Profile

BVS ยท NASDAQ
Cash & Cash Equivalents51.24M
Net Receivables128.30M
Inventory82.24M
Other Current Assets11.06M
Total Current Assets273 M
Property, Plant & Equipment27.02M
Goodwill & Intangible Assets375.88M
Long-Term Investments0.00
Other Non-Current Assets2.29M
Total Non-Current Assets29 M
Total Assets
683.56M

Financial Health Analysis

Current Ratio

1.70x

Strong liquidity. The company has adequate resources to meet short-term liabilities.

Debt-to-Equity Ratio

1.99x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

112 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

40% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Bioventus Inc. Balance Sheet

BVS โ€ข NASDAQ

Bioventus Inc. Balance SheetDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2015Dec 2014
ASSETS
CURRENT ASSETS
51.2M
41.6M
37M
30.2M
43.9M
86.8M
64.5M
42.8M
5M
15.8M
51.2M
41.6M
37M
30.2M
43.9M
86.8M
64.5M
42.8M
5M
15.8M
128.3M
127.4M
122.8M
136.3M
125M
88.3M
85.1M
73M
54.5M
47.1M
128.5M
127.4M
122.8M
136.3M
125M
88.3M
85.1M
73M
54.5M
46.6M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
498K
82.2M
92.5M
91.3M
84.8M
61.7M
29.1M
27.3M
27.4M
35.2M
26.7M
0.0
0.0
0.0
4.4M
12.2M
7.6M
6.1M
4.9M
4.4M
5.7M
11.1M
14.2M
16.9M
16.9M
20.3M
0.0
0.0
224K
343K
0.0
272.8M
275.6M
268M
272.6M
263.1M
211.8M
183M
148.4M
99.4M
95.2M
NON-CURRENT ASSETS
27M
33.5M
50M
44.1M
40.2M
21.8M
19.8M
4.8M
9.6M
10.4M
7.5M
7.5M
7.5M
7.5M
147.6M
49.8M
49.8M
49.8M
58.7M
50M
368.4M
404.7M
482.4M
639.9M
695.2M
191.7M
216.5M
237M
319.2M
274.3M
375.9M
412.2M
489.8M
647.3M
842.8M
241.5M
266.3M
286.8M
377.8M
324.3M
0.0
0.0
0.0
2.6M
29.3M
19.4M
3.3M
2.8M
0.0
0.0
5.5M
4.7M
0.0
0.0
481K
0.0
0.0
0.0
84K
179K
2.3M
1.9M
3.1M
406M
50M
0.0
0.0
0.0
393K
298K
410.7M
452.3M
542.9M
1.1B
962.8M
282.7M
289.4M
294.4M
387.9M
335.2M
683.6M
728M
810.9M
1.4B
1.2B
494.5M
472.4M
442.7M
487.4M
430.4M
LIABILITIES
CURRENT LIABILITIES
16.1M
27.6M
27.8M
39.3M
25.1M
6.9M
9M
8.2M
8.4M
6.7M
10.9M
23.7M
23M
36.7M
16.9M
4.4M
6.4M
8.2M
8.4M
5.4M
5.1M
3.9M
4.7M
2.6M
8.1M
2.4M
2.6M
0.0
0.0
1.3M
0.0
104.4M
85.6M
80.6M
91.3M
79.9M
47M
26.2M
14.9M
16M
19.2M
27.3M
27.8M
33.1M
18M
15M
10M
5.3M
36.5M
7.2M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
1.2M
688K
0.0
3.9M
4.7M
2.6M
8.1M
2.4M
2.6M
2M
2.7M
1.3M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
-1.3M
125.1M
51.1M
34.2M
151.1M
46.5M
20.9M
23M
25.7M
26.8M
21.6M
160.4M
210.4M
175.5M
304M
180.9M
122.6M
89M
65.4M
87.7M
52.2M
NON-CURRENT LIABILITIES
279M
308.3M
367M
385M
339.6M
173.4M
188M
189.6M
157.6M
162.3M
433K
564K
1.2M
2.2M
133.5M
3.4M
3.9M
4M
8.8M
9.3M
2.2M
23.1M
46.1M
269.2M
38.1M
51M
45.9M
38.5M
39.7M
28.3M
294.7M
332M
414.3M
656.4M
511.2M
227.7M
237.8M
232M
207.3M
200.8M
13.2M
0.0
0.0
0.0
0.0
0.0
0.0
55K
2.4M
1.5M
455.1M
542.4M
589.8M
960.4M
692.1M
350.3M
326.8M
297.5M
295M
252.9M
SHAREHOLDERS' EQUITY
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
168M
118M
83K
82K
79K
78K
75K
285.2M
285.1M
285.2M
113.4M
113.4M
520.9M
505.5M
494.3M
490.6M
465.3M
0.0
0.0
0.0
0.0
0.0
-334.9M
-355.1M
-321.5M
-165.3M
-6.6M
-144.5M
-141.7M
-139.8M
-91.8M
-56.5M
-1.9M
-2.6M
794K
-110K
179K
1.6M
-465K
-65K
-650K
14K
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
3.5M
2.6M
184.1M
147.9M
173.6M
325.2M
458.9M
142.2M
143M
145.3M
192.3M
177.5M
228.4M
185.6M
221.1M
412.2M
533.8M
144.2M
145.6M
145.3M
192.3M
177.5M
44.3M
37.7M
47.5M
87M
74.9M
1.9M
2.6M
0.0
0.0
0.0
SUMMARY
683.6M
728M
810.9M
1.4B
1.2B
494.5M
472.4M
442.7M
487.4M
430.4M
0.0
0.0
0.0
2.6M
29.3M
19.4M
3.3M
2.8M
0.0
0.0
311.3M
335.6M
394.8M
418.1M
357.7M
188.4M
198M
194.8M
196.5M
171M
260.1M
294M
357.9M
387.9M
313.7M
101.5M
133.4M
152.1M
191.6M
155.2M
66,926,984
66,926,984
66,926,984
66,926,984
66,926,984
66,926,984
66,926,984
66,926,984
66,926,984
66,926,984

SEC Filings

BVS - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 21, 2026
May 21, 2026
2026
10-Q

10-Q 2026 Q1

Q1

May 06, 2026
March 28, 2026
2026
8-K

8-K 2026

N/A

May 06, 2026
May 06, 2026
2026
DEF 14A

DEF 14A 2025

N/A

April 22, 2026
December 31, 2025
2025
10-K

10-K 2025 FY

FY

March 05, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

March 05, 2026
March 05, 2026
2026
8-K

8-K 2025

N/A

November 17, 2025
November 14, 2025
2025
10-Q

10-Q 2025 Q3

Q3

November 04, 2025
September 27, 2025
2025
8-K

8-K 2025

N/A

November 04, 2025
November 04, 2025
2025
8-K

8-K 2025

N/A

August 06, 2025
August 06, 2025
2025
Showing 1 to 10 of 108 filings